Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (93) 93
life sciences & biomedicine (91) 91
oncology (85) 85
humans (57) 57
breast cancer (55) 55
female (52) 52
middle aged (37) 37
adult (32) 32
breast neoplasms - drug therapy (32) 32
aged (31) 31
cancer (28) 28
tumors (23) 23
metastasis (22) 22
antineoplastic combined chemotherapy protocols - therapeutic use (19) 19
chemotherapy (19) 19
treatment outcome (19) 19
breast neoplasms - pathology (18) 18
patients (17) 17
antineoplastic combined chemotherapy protocols - adverse effects (16) 16
metastases (16) 16
cancer therapies (15) 15
clinical trials (15) 15
male (13) 13
medicine & public health (13) 13
trastuzumab (13) 13
breast neoplasms - metabolism (12) 12
neoplasm staging (12) 12
antibodies, monoclonal, humanized - adverse effects (11) 11
antineoplastic agents - therapeutic use (11) 11
care and treatment (11) 11
neoplasm metastasis (11) 11
research (11) 11
toxicity (11) 11
drug therapy (10) 10
aged, 80 and over (9) 9
antibodies, monoclonal, humanized - administration & dosage (9) 9
biological and medical sciences (9) 9
erbb-2 protein (9) 9
immunotherapy (9) 9
medical sciences (9) 9
mutation (9) 9
risk factors (9) 9
antineoplastic agents (8) 8
breast neoplasms - mortality (8) 8
chemotherapy, adjuvant (8) 8
disease-free survival (8) 8
dose-response relationship, drug (8) 8
health aspects (8) 8
metastatic breast cancer (8) 8
neoplasms - drug therapy (8) 8
paclitaxel - administration & dosage (8) 8
receptor, erbb-2 - genetics (8) 8
receptor, erbb-2 - metabolism (8) 8
antineoplastic agents - adverse effects (7) 7
biomarkers (7) 7
survival (7) 7
triple negative breast neoplasms - drug therapy (7) 7
abridged index medicus (6) 6
analysis (6) 6
antibodies, monoclonal, humanized - therapeutic use (6) 6
antineoplastic agents - administration & dosage (6) 6
antineoplastic agents, immunological - adverse effects (6) 6
breast neoplasms - diagnosis (6) 6
epidermal growth factor (6) 6
her2 (6) 6
medical prognosis (6) 6
multiple tumors. solid tumors. tumors in childhood (6) 6
prognosis (6) 6
abemaciclib (5) 5
breast neoplasms - genetics (5) 5
camptothecin - adverse effects (5) 5
camptothecin - analogs & derivatives (5) 5
cyclin-dependent kinase 4 (5) 5
gynecology. andrology. obstetrics (5) 5
hematology, oncology and palliative medicine (5) 5
her2-positive (5) 5
human necessities (5) 5
hygiene (5) 5
immune checkpoint inhibitors (5) 5
mammary gland diseases (5) 5
medical or veterinary science (5) 5
monoclonal antibodies (5) 5
neoadjuvant therapy (5) 5
original reports (5) 5
paclitaxel - adverse effects (5) 5
patient outcomes (5) 5
preparations for medical, dental, or toilet purposes (5) 5
progression-free survival (5) 5
receptor, erbb-2 - antagonists & inhibitors (5) 5
receptors, estrogen - metabolism (5) 5
ribociclib (5) 5
solid tumors (5) 5
specific therapeutic activity of chemical compounds ormedicinal preparations (5) 5
trastuzumab - administration & dosage (5) 5
antimitotic agents (4) 4
antineoplastic agents, immunological - therapeutic use (4) 4
biomarkers, tumor (4) 4
biopsy (4) 4
breast neoplasms (4) 4
breast neoplasms - complications (4) 4
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text HER2-positive breast cancer: new therapeutic frontiers and overcoming resistance
by Pernas, Sonia and Tolaney, Sara M
3/2019, Volume 11, 16
tyrosine kinase inhibitors | new anti-HER2 therapies | novel combinations | drug–antibody conjugates | HER2-positive | breast cancer | resistance | Life Sciences & Biomedicine | Oncology | Science & Technology
Book Review
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
by Bardia, Aditya and Mayer, Ingrid A and Vahdat, Linda T and Tolaney, Sara M and Isakoff, Steven J and Diamond, Jennifer R and O’Shaughnessy, Joyce and Moroose, Rebecca L and Santin, Alessandro D and Abramson, Vandana G and Shah, Nikita C and Rugo, Hope S and Goldenberg, David M and Sweidan, Ala M and Iannone, Robert and Washkowitz, Sarah and Sharkey, Robert M and Wegener, William A and Kalinsky, Kevin
The New England journal of medicine, ISSN 0028-4793, 02/2019, Volume 380, Issue 8, pp. 741 - 751
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Irinotecan - administration & dosage | Humans | Middle Aged | Cell Adhesion Molecules - antagonists & inhibitors | Male | Antineoplastic Agents - therapeutic use | Diarrhea - chemically induced | Triple Negative Breast Neoplasms - drug therapy | Dose-Response Relationship, Drug | Antineoplastic Agents - adverse effects | Aged, 80 and over | Immunoconjugates - therapeutic use | Adult | Female | Neutropenia - chemically induced | Camptothecin - analogs & derivatives | Immunoconjugates - adverse effects | Antibodies, Monoclonal, Humanized - adverse effects | Camptothecin - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Antigens, Neoplasm | Camptothecin - therapeutic use | Anemia - chemically induced | Survival Rate | Triple Negative Breast Neoplasms - mortality | Irinotecan - adverse effects | Progression-Free Survival | Aged | Infusions, Intravenous | Complications and side effects | Anemia | Dosage and administration | Breast cancer | Drug therapy | Risk factors | Antibody-drug conjugates | Data analysis | Nuclear magnetic resonance--NMR | Medical imaging | Body weight | Metastasis | FDA approval | Cancer therapies | Patients | Cell surface | Metastases | Chemotherapy | Medical prognosis | Response rates | Monoclonal antibodies | Solid tumors | Drug dosages | Neutropenia | Tumors | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text CDK4/6 inhibitors in breast cancer: a role in triple-negative disease?
by Goel, Shom and Tolaney, Sara M
The lancet oncology, ISSN 1470-2045, 11/2019, Volume 20, Issue 11, pp. 1479 - 1481
Life Sciences & Biomedicine | Oncology | Science & Technology | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text CDK4/6 inhibition in breast cancer: current practice and future directions
by Pernas, Sonia and Tolaney, Sara M and Winer, Eric P and Goel, Shom
7/2018, Volume 10, 15
triple-negative breast cancer | CDK4/6 inhibitors | HER2-positive | breast cancer | predictors of response/resistance | PI3K inhibitors | immune checkpoint blockade | Life Sciences & Biomedicine | Oncology | Science & Technology
Book Review
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints
by Chang, Lee-Shing and Barroso-Sousa, Romualdo and Tolaney, Sara M and Hodi, F Stephen and Kaiser, Ursula B and Min, Le
Endocrine reviews, ISSN 0163-769X, 02/2019, Volume 40, Issue 1, pp. 17 - 65
Life Sciences & Biomedicine | Endocrinology & Metabolism | Science & Technology | Antineoplastic Agents, Immunological - toxicity | Hypophysitis - chemically induced | Antineoplastic Agents, Immunological - adverse effects | Humans | Diabetes Mellitus, Type 1 - chemically induced | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Addison Disease - chemically induced | CTLA-4 Antigen - antagonists & inhibitors | Thyroid Diseases - chemically induced | Immunotherapy - adverse effects | Neoplasms - drug therapy | Complications and side effects | Care and treatment | Usage | Immunotherapy | Monoclonal antibodies | Physiological aspects | Endocrine gland diseases | Development and progression | Methods | Risk factors | Cancer | Corticoids | Therapy | Adrenal glands | PD-1 protein | Toxicity | Antibodies | Homeostasis | Cytotoxicity | Lymphocytes T | Thyroid gland | Subgroups | Anticancer properties | CTLA-4 protein | Lymphocytes | Immune system | Thyroid | Corticosteroids | Diabetes mellitus | FDA approval | Hypothyroidism | Insulin | Immune checkpoint | Antitumor activity | Diabetes | Apoptosis | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Optimal treatment of early stage HER2‐positive breast cancer
by Pernas, Sonia and Barroso‐Sousa, Romualdo and Tolaney, Sara M
Cancer, ISSN 0008-543X, 12/2018, Volume 124, Issue 23, pp. 4455 - 4466
breast cancer | human epidermal growth factor 2 (HER2)‐positive | de‐escalation treatment | novel anti‐HER2 therapies | early stage | novel anti-HER2 therapies | de-escalation treatment | human epidermal growth factor 2 (HER2)-positive | Life Sciences & Biomedicine | Oncology | Science & Technology | Therapy | Prognosis | Toxicity | Medical treatment | Clinical trials | Breast cancer | Cancer therapies | Patients | Survival | ErbB-2 protein | Subgroups | Optimization | Metastases | Heterogeneity | Epidermal growth factor | Inhibitors | Medical prognosis | Monoclonal antibodies | Growth factors | Trastuzumab | Cancer | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights